scPharmaceuticals Inc. (SCPH): Price and Financial Metrics
SCPH Price/Volume Stats
| Current price | $4.57 | 52-week high | $12.75 |
| Prev. close | $4.56 | 52-week low | $4.25 |
| Day low | $4.45 | Volume | 113,900 |
| Day high | $4.66 | Avg. volume | 227,032 |
| 50-day MA | $5.33 | Dividend yield | N/A |
| 200-day MA | $6.24 | Market Cap | 164.77M |
SCPH Stock Price Chart Interactive Chart >
scPharmaceuticals Inc. (SCPH) Company Bio
scPharmaceuticals Inc. engages in the development and commercialization of transformative pharmaceutical products. The company’s under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.
Latest SCPH News From Around the Web
Below are the latest news stories about SCPHARMACEUTICALS INC that investors may wish to consider to help them evaluate SCPH as an investment opportunity.
scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2023 Earnings Call TranscriptscPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2023 Earnings Call Transcript November 8, 2023 scPharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.36. Operator: Thank you for standing by. This is the conference operator. Welcome to the scPharmaceuticals Third Quarter 2023 Earnings Conference Call. As a reminder, all participants are in listen-only mode […] |
scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business UpdateGenerated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments of $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLINGTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduc |
scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023Management to host conference call and webcast at 4:30 p.m. ETBURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 8, 2023, to discuss the financial res |
scPharmaceuticals to Participate in Two Upcoming Investor ConferencesBURLINGTON, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences. Event: Jefferies London Healthcare ConferenceTuesday, November 14, 2023Fireside chat |
Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 47%While scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders are probably generally happy, the stock hasn't had... |
SCPH Price Returns
| 1-mo | -11.61% |
| 3-mo | -13.28% |
| 6-mo | -19.40% |
| 1-year | -55.02% |
| 3-year | -32.60% |
| 5-year | 26.94% |
| YTD | -27.11% |
| 2023 | -12.55% |
| 2022 | 42.83% |
| 2021 | -5.10% |
| 2020 | -6.54% |
| 2019 | 50.53% |
Loading social stream, please wait...